Cancer biomarker profiling in patients with chronic hepatitis C virus, liver cirrhosis and hepatocellular carcinoma

Oncology Reports

Volumn 29, Issue 6, 2013, Pages 2163-2168

  Costantini, Susan ^a   Capone, Francesca ^a   Maio, Patrizia ^b   Guerriero, Eliana ^a   Colonna, Giovanni ^c   Izzo, Francesco ^a   Castello, Giuseppe ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b S G MOSCATI HOSPITAL   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Angiogenic factors; Bio Plex; Chronic hepatitis C; Cirrhosis; Hepatitis C virus; Hepatocellular carcinoma; Interactomic studies

Indexed keywords

ANGIOGENIC FACTOR; CD31 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR; FOLLISTATIN; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 6 RECEPTOR ALPHA; LEPTIN; OSTEOPONTIN; PLATELET DERIVED GROWTH FACTOR AB; PLATELET DERIVED GROWTH FACTOR BB; PROLACTIN; SCATTER FACTOR; STEM CELL FACTOR; TUMOR MARKER; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ADULT; AGED; ARTICLE; BIOASSAY; CHILD PUGH SCORE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HEPATITIS C; HUMAN; INFLAMMATION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TUMOR VOLUME;

AGED; ANTIGENS, CD31; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; FEMALE; HEPATITIS C, CHRONIC; HEPATOCYTE GROWTH FACTOR; HUMANS; INTERLEUKIN-6 RECEPTOR ALPHA SUBUNIT; LEPTIN; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; PROLACTIN; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL;

EID: 84876250632     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2378     Document Type: Article

References (33)

1. Fusco M, Girardi E, Piselli P, Palombino R, Polesel J, Maione C, Scognamiglio P, Pisanti FA, Solmone M, Di Cicco P, Ippolito G, Franceschi S and Serraino D: Epidemiology of viral hepatitis infections in an area of southern Italy with high incidence rates of liver cancer. Eur J Cancer 44: 847-853, 2008.
2. El-Serag HB and Rudolph KL: Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132: 2557-2576, 2007. (Pubitemid 46890874)
3. Castello G, Scala S, Palmieri G, Curley SA and Izzo F: HCV-related hepatocellular carcinoma: From chronic inflammation to cancer. Clin Immunol 134: 237-250, 2010.
4. Ueno Y, Sollano JD and Farrell GC: Prevention of hepatocellular carcinoma complicating chronic hepatitis C. J Gastroenterol Hepatol 24: 531-536, 2009.
5. Behne T and Copur MS: Biomarkers for hepatocellular carcinoma. Int J Hepatol 2012: 859076, 2012.
6. Forner A, Vilana R, Ayuso C, Bianchi L, Solé M, Ayuso JR, Boix L, Sala M, Varela M, Llovet JM, Brú C and Bruix J: Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology 47: 97-104, 2008. (Pubitemid 351171046)
7. Carmeliet P: Angiogenesis in health and disease. Nat Med 9: 653-660, 2003.
8. Semela D and Dufour JF: Angiogenesis and hepatocellular carcinoma. J Hepatol 41: 864-880, 2004. (Pubitemid 39434320)
9. Zhang JK, Pan PL, Wu YM, Xiao JJ and Peng JW: Expression of HER-2/neu oncogene in hepatocellular carcinoma and the clinical implications. Nan Fang Yi Ke Da Xue Xue Bao 30: 326-328, 2010 (In Chinese).
10. Li D, Chiu H, Gupta V and Chan DW: Validation of a multiplex immunoassay for serum angiogenic factors as biomarkers for aggressive prostate cancer. Clin Chim Acta 413: 1506-1511, 2012.
11. Capone F, Costantini S, Guerriero E, Calemma R, Napolitano M, Scala S, Izzo F and Castello G: Serum cytokine levels in patients with hepatocellular carcinoma. Eur Cytokine Netw 21: 99-104, 2010.
12. Costantini S, Capone F, Guerriero E, Maio P, Colonna G and Castello G: Serum cytokine levels as putative prognostic markers in the progression of chronic HCV hepatitis leading to cirrhosis. Eur Cytokine Netw 21: 251-256, 2010.
13. Costantini S, Capone F, Guerriero E, Marfella R, Sorice A, Maio P, Di Stasio M, Paolisso G, Castello G and Colonna G: Cytokinome profile of patients with type 2 diabetes and/or chronic hepatitis C infection. PLoS One 7: e39486, 2012.
14. Bacaksiz A, Sahin FI, Bilezikci B and Yilmaz Z: Determination of HER-2/Neu status in hepatocellular carcinoma cases. Genet Test 12: 211-214, 2008. (Pubitemid 351860439)
15. Rose-John S: Interleukin-6 biology is coordinated by membrane bound and soluble receptors. Acta Biochim Pol 50: 603-611, 2003.
16. Rose-John S and Heinrich PC: Soluble receptors for cytokines and growth factors: generation and biological function. Biochem J 300: 281-290, 1994. (Pubitemid 24167878)
17. Montero-Julian FA: The soluble IL-6 receptors: serum levels and biological function. Cell Mol Biol 47: 583-597, 2001.
18. Migita K, Abiru S, Maeda Y, Daikoku M, Ohata K, Nakamura M, Komori A, Yano K, Yatsuhashi H, Eguchi K and Ishibashi H: Serum levels of interleukin-6 and its soluble receptors in patients with hepatitis C virus infection. Hum Immunol 67: 27-32, 2006.
19. Maione D, Di Carlo E, Li W, Musiani P, Modesti A, Peters M, Rose-John S, Della Rocca C, Tripodi M, Lazzaro D, Taub R, Savino R and Ciliberto G: Coexpression of IL-6 and soluble IL-6R causes nodular regenerative hyperplasia and adenomas of the liver. EMBO J 17: 5588-5597, 1998. (Pubitemid 28445970)
20. Balci H, Akgun-Dar K, Gazioglu N, Kapucu A, Bolayirli M and Oz B: The relationship between prolactin (PRL), leptin, nitric oxide (NO), and cytokines in patients with hyperprolactinemia. Pituitary 12: 170-176, 2009.
21. Reeves HL and Friedman SL: Activation of hepatic stellate cells - a key issue in liver fibrosis. Front Biosci 7: d808-d826, 2002.
22. Otte C, Otte JM, Strodthoff D, Bornstein SR, Fölsch UR, Mönig H and Kloehn S: Expression of leptin and leptin receptor during the development of liver fibrosis and cirrhosis. Exp Clin Endocrinol Diabetes 112: 10-17, 2004. (Pubitemid 38220427)
23. Katz SC, Pillarisetty VG, Bleier JI, Shah AB and DeMatteo RP: Liver sinusoidal endothelial cells are insufficient to activate T cells. J Immunol 173: 230-235, 2004. (Pubitemid 38797346)
24. Newman PJ and Newman DK: Signal transduction pathways mediated by PECAM-1. New roles for an old molecule in platelet and vascular biology. Arterioscler Thromb Vasc Biol 23: 953-964, 2003. (Pubitemid 36713547)
25. Kukla M, Zwirska-Korczala K, Gabriel A, Janczewska-Kazek E, Berdowska A, Wiczkowski A, Rybus-Kalinowska B, Kalinowski M, Ziolkowski A, Wozniak-Grygiel E, Waluga M and Nowak B: sPECAM-1 and sVCAM-1: role in pathogenesis and diagnosis of chronic hepatitis C and association with response to antiviral therapy. Therap Adv Gastroenterol 2: 79-90, 2009.
26. Kollerová J, Koller T and Payer J: Endocrine changes in liver disease. Vnitr Lek 58: 24-30, 2012 (In Slovak).
27. Simon-Holtorf J, Mönig H, Klomp HJ, Reinecke-Lüthge A, Fölsch UR and Kloehn S: Expression and distribution of prolactin receptor in normal, fibrotic, and cirrhotic human liver. Exp Clin Endocrinol Diabetes 114: 584-589, 2006. (Pubitemid 46087265)
28. Payer J, Koller T, Baqi L and Kollerova J: Prolactin levels in patients with cirrhosis increase with severity of liver disease. Endocrine Abstracts 16: P436, 2008.
29. Gentile A, Trusolino L and Comoglio PM: The Met tyrosine kinase receptor in development and cancer. Cancer Metastasis Rev 27: 85-94, 2008.
30. Sahu A: Leptin signaling in the hypothalamus: emphasis on energy homeostasis and leptin resistance. Front Neuroendocrinol 24: 225-253, 2003.
31. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Müller-Newen G and Schaper F: Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 15: 1-20, 2003. (Pubitemid 37046923)
32. Pancholi S, Lykkesfeldt AE, Hilmi C, Banerjee S, Leary A, Drury S, Johnston S, Dowsett M and Martin L-A: ERBB2 influences the subcellular localization of the estrogen receptor in tamoxifen-resistant MCF-7 cells leading to the activation of AKT and RPS6KA2. Endocr Relat Cancer 15: 985-1002, 2008.
33. Naldini L, Vigna E, Narsimhan RP, Gaudino G, Zarnegar R, Michalopoulos GK and Comoglio PM: Hepatocyte growth factor (HGF) stimulates the tyrosine kinase activity of the receptor encoded by the proto-oncogene c-MET. Oncogene 6: 501-504, 1991. (Pubitemid 21924112)